Historical Information

BASKING RIDGE, N.J. (August 30, 2018)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications,  announces today that David J.

Caladrius Biosciences Reports 2018 Second Quarter and First Six Months Financial Results Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (August 9, 2018)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical

Caladrius Biosciences to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018 at 4:30 p.m. ET BASKING RIDGE, N.J. (August 2, 2018)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple

BASKING RIDGE, N.J. (June 19, 2018)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases, announces today that the U.S.

Caladrius Biosciences Sells Rights to Counter-Flow  Centrifugation System to Hitachi Chemical Advanced Therapeutics Solutions Sale of non-core asset brings $2.5 million in non-dilutive funding BASKING RIDGE, N.J. (June 5, 2018)  – Caladrius Biosciences, Inc.

Caladrius Biosciences Reports 2018 First Quarter Financial Results Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (May 10, 2018)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple

Caladrius Biosciences to Host First Quarter 2018 Financial Results Conference Call on Thursday, May 10, 2018 at 4:30 p.m. Eastern Time BASKING RIDGE, N.J. (May 3, 2018)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with

BASKING RIDGE, N.J. (April 10, 2018)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces today that the Company has received

BASKING RIDGE, N.J. (April 9, 2018)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces today that Douglas Losordo, M.D.,

Caladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (March 22, 2018)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company